Moderna Inc. (NASDAQ: MRNA) reported total revenue of $5.1 billion for the fourth quarter of 2022, down 29% year-over-year due to a drop in COVID-19 vaccine sales.
Net income decreased by 70% to $1.5 billion while EPS dropped by 68% to $3.61 compared to the same period last year.
The company expects product sales of approx. $2 billion in the first half of 2023.